Envestnet Asset Management Inc. lessened its position in Dexcom (NASDAQ:DXCM) by 63.7% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,661 shares of the medical device company’s stock after selling 9,932 shares during the quarter. Envestnet Asset Management Inc.’s holdings in Dexcom were worth $324,000 as of its most recent filing with the SEC.
Other institutional investors have also recently made changes to their positions in the company. American International Group Inc. acquired a new stake in Dexcom in the 4th quarter valued at approximately $116,000. Thompson Davis & CO. Inc. acquired a new stake in Dexcom in the 4th quarter valued at approximately $137,000. Marco Investment Management LLC acquired a new stake in Dexcom in the 4th quarter valued at approximately $201,000. D.A. Davidson & CO. acquired a new stake in Dexcom in the 4th quarter valued at approximately $208,000. Finally, First Manhattan Co. acquired a new stake in Dexcom in the 4th quarter valued at approximately $223,000.
NASDAQ:DXCM opened at $73.42 on Wednesday. The company has a market cap of $6,296.85, a price-to-earnings ratio of -126.59 and a beta of -0.02. Dexcom has a twelve month low of $42.62 and a twelve month high of $81.91. The company has a current ratio of 5.36, a quick ratio of 5.04 and a debt-to-equity ratio of 0.78.
Dexcom (NASDAQ:DXCM) last issued its earnings results on Tuesday, February 27th. The medical device company reported $0.10 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.03 by $0.07. Dexcom had a negative return on equity of 13.99% and a negative net margin of 6.99%. The company had revenue of $221.00 million during the quarter, compared to the consensus estimate of $217.82 million. research analysts forecast that Dexcom will post -0.56 EPS for the current fiscal year.
In other news, EVP Richard Doubleday sold 1,635 shares of Dexcom stock in a transaction that occurred on Tuesday, January 23rd. The stock was sold at an average price of $54.67, for a total transaction of $89,385.45. Following the completion of the transaction, the executive vice president now directly owns 65,049 shares in the company, valued at approximately $3,556,228.83. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Chairman Terrance H. Gregg sold 10,000 shares of Dexcom stock in a transaction that occurred on Thursday, February 15th. The stock was sold at an average price of $55.91, for a total value of $559,100.00. Following the transaction, the chairman now owns 484,559 shares of the company’s stock, valued at $27,091,693.69. The disclosure for this sale can be found here. Insiders have sold a total of 25,854 shares of company stock valued at $1,572,481 over the last quarter. 1.70% of the stock is currently owned by corporate insiders.
A number of brokerages recently issued reports on DXCM. Northland Securities reissued a “sell” rating and issued a $40.00 target price on shares of Dexcom in a research report on Tuesday, January 16th. ValuEngine lowered Dexcom from a “hold” rating to a “sell” rating in a research report on Thursday, February 8th. Piper Jaffray set a $78.00 target price on Dexcom and gave the company a “buy” rating in a research report on Friday, March 23rd. Oppenheimer set a $80.00 target price on Dexcom and gave the company a “buy” rating in a research report on Thursday, March 29th. Finally, Zacks Investment Research raised Dexcom from a “sell” rating to a “hold” rating in a research report on Friday, March 16th. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, thirteen have given a buy rating and one has given a strong buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $67.38.
WARNING: “Envestnet Asset Management Inc. Sells 9,932 Shares of Dexcom (DXCM)” was originally reported by The Lincolnian Online and is the sole property of of The Lincolnian Online. If you are reading this article on another website, it was illegally stolen and reposted in violation of United States & international copyright & trademark law. The correct version of this article can be read at https://www.thelincolnianonline.com/2018/04/18/envestnet-asset-management-inc-sells-9932-shares-of-dexcom-dxcm.html.
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Dexcom (NASDAQ:DXCM).
Receive News & Ratings for Dexcom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dexcom and related companies with MarketBeat.com's FREE daily email newsletter.